TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00222521
Drug: Glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01154816
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01549106
Drug: IPI-145
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
Study: NCT00801099
Drug: Amoxicillin/Clavulanic Acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
Study: NCT04070235
Drug: Daclatasvir dihydrochloride
Normalized name: Daclatasvir dihydrochloride
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Study: NCT03596892
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Study: NCT03596892
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study: NCT04415918
Drug: Bezlotoxumab Injection
Normalized name: bezlotoxumab Injection
DrugBank: Bezlotoxumab (DB13140)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
Study: NCT00316004
Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study: NCT03895671
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day
Study: NCT03895671
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;
Study: NCT03397771
Drug: Litoxetine
Normalized name: Litoxetine
DrugBank: Litoxetine (DB15038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral study medication provided in a dose titration manner
Study: NCT00775905
Drug: amlodipine 10 mg tablet
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04062656
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
Study: NCT04062656
Drug: relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: relatlimab (80mg flat dose) administered IV over 60 min
Study: NCT04062656
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/m² IV over 1 h
Study: NCT04062656
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50mg/m² IV over 1 h
Study: NCT04062656
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil 2600mg/m² IV over 24h
Study: NCT01049711
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03208361
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03208361
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00620607
Drug: huC242-DM4
Normalized name: huMy9-6-DM4
DrugBank: AVE9633 (DB06318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
Study: NCT03247244
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 10%, CBD \<0.5%
Study: NCT03247244
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 8.6%, CBD 8.6%
Study: NCT03247244
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 0.6%, CBD 14%
Study: NCT03474497
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: • A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
Study: NCT03474497
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
Study: NCT01780987
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
Study: NCT00614393
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT01780987
Drug: Unfractionated Heparin (UFH)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
Study: NCT01780987
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing for 24 weeks to target INR range between 1.5-2.5
Study: NCT04602065
Drug: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
Normalized name: Recombinant human papillomavirus type 6 L1 protein
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI318, 300mg, Q2W, Intravenous influsion.
Study: NCT00140426
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
Study: NCT00130455
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00869596
Drug: fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
Study: NCT00869596
Drug: Comparator: Placebo to fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
Study: NCT00869596
Drug: Comparator: Lipopolysaccharide (LPS)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
Study: NCT00869596
Drug: Comparator: albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
Study: NCT00393367
Drug: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
Study: NCT00296634
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.
Study: NCT02323516
Drug: diosmectite + loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
Study: NCT02669758
Drug: ALKS 3831
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets were administered for daily dosing
Study: NCT04325763
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT04325763
Drug: TQB2450(blank)
Normalized name: BLACK 2
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Study: NCT04325763
Drug: Anlotinib(blank)
Normalized name: acid black 52
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study: NCT04041349
Drug: mouse nerve growth factor
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
Study: NCT00072592
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04047914
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
Study: NCT02908035
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
Study: NCT02908035
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
Study: NCT03545035
Drug: idelalisib and rituximab
Normalized name: Idelalisib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
Study: NCT02740387
Drug: OTO-104
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02325518
Drug: Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00393367
Drug: Prednisolone, prednisone, or methylprednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
Study: NCT02325518
Drug: Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00103818
Drug: gaboxadol
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 3 months
Study: NCT00054600
Drug: Methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02740699
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 40-80 mg once daily.
Study: NCT00152178
Drug: UFT (uracil, tegafur) and tamoxifen
Normalized name: tegafur / uracil
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
Study: NCT00152178
Drug: CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
Study: NCT00006083
Drug: Fragmin
Normalized name: Fragmin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin at 5000 IU injected subcutaneously daily
Study: NCT00040183
Drug: Tarceva (erlotinib HCl, OSI-774)
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00336245
Drug: Hormonal Contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534844
Drug: Parts A/B: Adrabetadex
DrugBank: Betadex (DB03995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
Study: NCT05268068
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT05268068
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) Injection
Study: NCT03512860
Drug: VAL
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03560986
Drug: Neridronic acid 100 mg
Normalized name: Neridronic Acid
DrugBank: Neridronic Acid (DB11620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
Study: NCT00019786
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01434186
Drug: Placebo matching with Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
Study: NCT01434186
Drug: Metformin IR
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
Study: NCT01434186
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
Study: NCT01434186
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
Study: NCT00831766
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
Study: NCT00831766
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
Study: NCT00831766
Drug: Lenalidomide (Revlimid®)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
Study: NCT02166814
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00482183
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03473626
Drug: Alicaforsen
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen tablet
Study: NCT01716624
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard oral therapy
Study: NCT01716624
Drug: Botulinum Toxin A injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 10 units/kg injected into the detrusor muscle using cystoscopy
Study: NCT04620135
Drug: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
DrugBank: Ripasudil (DB13165)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Other Name: Glanatec®
Study: NCT02229123
Drug: Intravenous Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
Study: NCT01162746
Drug: Intravitreal dexamethasone and intravitreal ranibizumab
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT.
Study: NCT01162746
Drug: Intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
Study: NCT00751907
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg daily for 4 months
Study: NCT00545675
Drug: Abilify(aripiprazole)
Normalized name: aripiprazole Injection [Abilify]
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
Study: NCT00545675
Drug: Depakote (divalproate)
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
Study: NCT02737527
Drug: 10 ml of 0.25% levobupivacaine injection for LSB
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
Study: NCT03566576
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
Study: NCT03566576
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
Study: NCT03566576
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
Study: NCT03250494
Drug: Dulox capsule (60mg)
Normalized name: duloxetine 60 MG Oral Capsule
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
Study: NCT03250494
Drug: a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
Study: NCT02803229
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no